Respiratory Medicine
Page 1 • 6 itemsUnlock global respiratory medicine market insights. Track drug development, regulatory approvals, and competitive intelligence for strategic pharma BD.
Trevi Therapeutics Schedules Q1 2026 Earnings Call for Haduvio Chronic Cough Treatment Updates
Trevi Therapeutics will report Q1 2026 financial results and provide corporate updates on Haduvio development for chronic cough treatment on May 5, 2026.
AstraZeneca's BREZTRI Aerosphere Approved as First Triple Therapy for Asthma in Patients 12 and Older
AstraZeneca receives FDA approval for BREZTRI Aerosphere as the first and only triple-combination therapy for asthma maintenance treatment in patients aged 12+.
Cipla Receives FDA Approval for First Generic Ventolin HFA (Albuterol Sulfate) - AB-Rated Therapeutic Equivalent
Cipla secures FDA approval for first AB-rated generic Ventolin HFA (albuterol sulfate), offering cost-effective asthma treatment alternative to patients.
Tozorakimab Meets Primary Endpoint in Phase III COPD Trial, Shows Significant Reduction in Exacerbations
First-in-class tozorakimab demonstrates statistically significant reduction in COPD exacerbations across all patient populations in pivotal Phase III MIRANDA trial.
Nuance Pharma's Ohtuvayre Shows Improved Lung Function in Chinese COPD Patients - ENHANCE-CHINA Phase 3 Results Published
Nuance Pharma announces CHEST journal publication of Phase 3 ENHANCE-CHINA trial showing Ohtuvayre (ensifentrine) improved lung function in Chinese COPD patients.
Amneal Pharmaceuticals Launches First Respiratory Inhalers: Albuterol and Beclomethasone HFA Products Now Available
Amneal Pharmaceuticals launches FDA-approved albuterol sulfate and beclomethasone dipropionate HFA inhalers, marking company's entry into respiratory market.